Skip to content
Companies

Skybound Medtech

Houston-based medical technology company developing dual-use biomedical platforms for both spaceflight and terrestrial medicine

Raised to date

$1.3M

of $1.3M offered across 1 Form D filing

Investors
5
Last filed
Jul 9, 2026

About

It works on the physiological barriers that limit long-duration human presence off-planet - musculoskeletal, neuro-ocular, immune, and genomic degradation - and builds platform technologies, medical devices, digital-health tools, and medical-manufacturing capability against them. The company positions Houston as its base because it co-locates the Texas Medical Center, NASA's Johnson Space Center, and venture capital. Founder and CEO Matthew Kuhn has said the company intends to launch ten dual-use medtech spinouts over the next decade.

Builds medical technology against spaceflight-induced physiological degradation and commercializes the same platforms into terrestrial clinical, longevity, and defense markets, rather than treating space medicine as a single-market niche.

Funding

  • EquityFiled Jul 9, 2026Form D
    $1.3M/ $1.3M

Product

Dual-use medical technology platforms

Medical technology R&D platform

Platform technologies, medical devices, and digital-health tools developed against four categories of spaceflight-induced physiological degradation: musculoskeletal, neuro-ocular, immune, and genomic. Skybound identifies the physiological barrier, builds and de-risks the technology, then commercializes it across space, defense, and terrestrial medicine.

  • Musculoskeletal degradation countermeasures
  • Neuro-ocular barrier research
  • Immune system and genomic degradation programs

Built for

Human spaceflight programs and commercial space operators, national defense, and terrestrial clinical medicine

People on file